Cost of Revenue Trends: PTC Therapeutics, Inc. vs Ligand Pharmaceuticals Incorporated

Biotech Cost Trends: PTC vs. Ligand from 2014-2023

__timestampLigand Pharmaceuticals IncorporatedPTC Therapeutics, Inc.
Wednesday, January 1, 2014913600079838000
Thursday, January 1, 20155807000121816000
Friday, January 1, 20165571000117633000
Sunday, January 1, 201753660004577000
Monday, January 1, 2018633700012670000
Tuesday, January 1, 20191134700012135000
Wednesday, January 1, 20203041900018942000
Friday, January 1, 20216217600032328000
Saturday, January 1, 20225282700044678000
Sunday, January 1, 20233504900065486000
Loading chart...

Unlocking the unknown

Cost of Revenue Trends: A Tale of Two Biotechs

In the ever-evolving landscape of biotechnology, understanding cost dynamics is crucial. This chart offers a fascinating glimpse into the cost of revenue trends for PTC Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated from 2014 to 2023. Over this period, PTC Therapeutics experienced a significant fluctuation, with costs peaking in 2015 at approximately 121.8 million, before stabilizing around 65.5 million in 2023. In contrast, Ligand Pharmaceuticals maintained a more consistent trajectory, with a notable spike in 2021, reaching around 62.2 million, before settling at 35 million in 2023.

These trends highlight the contrasting strategies and market responses of these two companies. While PTC Therapeutics shows a more volatile pattern, Ligand Pharmaceuticals demonstrates a steadier approach. This analysis provides valuable insights for investors and industry analysts seeking to understand the financial health and strategic direction of these biotech firms.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025